TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02971501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04084938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate operation or prostate artery embolization
Description: As described above.
Study: NCT02971501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study: NCT03067181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo observation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT00181753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours of primed constant infusion
Study: NCT03067181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT00181753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours of primed constant infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours of primed constant infusion
Study: NCT03067181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Test
Description: Undergo a pulmonary function test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Test
Description: Undergo a pulmonary function test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Test
Description: Undergo a pulmonary function test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Test
Description: Undergo a pulmonary function test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04591574

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Red Blood Cells (Transfusion)
Description: Participants will receive RBC transfusions in accordance with trial protocol (intervention group) or usual care, which is in accordance with the NICE guidelines

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cells (Transfusion)
Description: Participants will receive RBC transfusions in accordance with trial protocol (intervention group) or usual care, which is in accordance with the NICE guidelines
Study: NCT03108196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sigmoid
Description: The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.
Study: NCT02449954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine sulphate
Description: Group I:received IV 0.1mg/kg morphine sulphate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tramadol HCL
Description: Group II:received IV 2 mg/kg tramadol HCL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous ketorolac tromethamine
Description: Group III: received IV 30 mg ketorolac tromethamine
Study: NCT02917551

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7 days of adequate antibiotic treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14 days of adequate antibiotic treatment
Study: NCT03904641

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: aPDT
Description: For aPDT, PapacarieMblue (Fórmula e Ação) will be used. It will be left for 5 minutes in the cavity. The carious tissue will be removed and the application of the PapacarieMblue will be repeated. The tissue will then be irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART
Description: Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART
Description: Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
Study: NCT03108196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ileal
Description: The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped ﬂap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.
Study: NCT03352765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: bendamustine 160 mg/m2 intravenously on days -3 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation (ASCT)
Description: reinfusion of autologous stem cells on day 0.
Study: NCT03038672

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04727502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: duloxetine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregablin
Description: Pregablin
Study: NCT03038672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlilumab
Description: Given IV
Study: NCT00317837

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unipolar Hemiarthroplasty of the hip joint
Description: Unipolar Hemiarthroplasty of the hip joint

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bipolar hemiarthroplasty
Description: bipolar hemiarthroplasty
Study: NCT02915497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abbreviated Early Prolonged Exposure Therapy
Description: Since many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).
Study: NCT02969577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Participants will have a personal training session at the first visit. A member of the study team will discuss strength training and cardiovascular workouts for them to complete over the first 6 months of the study. A member of the study team will then talk with the participant every week for the first 3 months and monthly afterwards until month 6. Participants will be sent exercise videos and be given recommendations for the exercise program via phone calls and will be tailored to the individual. Videos and recommendations will be sent directly to the participant's smartphone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Nutrition Coaching
Description: Diet and nutrition coaching session with an overview of resources on the smartphone. Over the first 6 months, participants will receive healthy recipes and nutritional information on the smartphone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care with Attention
Description: Participants will receive the usual care for men undergoing ADT. This includes monitoring blood work and answering questions about how they are feeling. Participants will be directed to the IMPACT website for education materials on prostate cancer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care with Attention
Description: Participants will receive the usual care for men undergoing ADT. This includes monitoring blood work and answering questions about how they are feeling. Participants will be directed to the IMPACT website for education materials on prostate cancer.
Study: NCT03209258

Intervention type: OTHER
Group type: OTHER
Intervention: Care bundle of active management
Description: 1. Intensive BP lowering to systolic target of \<140mmHg;~2. Glucose control target 6.1-7.8 mmol/l for non-diabetic; 7.8-10.0 mmol/l for diabetic patients;~3. Treatment of pyrexia to a target body temperature ≤37.5 ℃;~4. Reversal of anticoagulation to target INR \<1.5 involving use of vitamin K and prothrombin complex concentrate (PCC) or alternatively, fresh frozen plasma (FFP).~As the trial is an assessment of care bundle of physiological management, there is some flexibility in the use of particular BP lowering agents and antipyretic agents to achieve targets.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
Study: NCT03419494

Intervention type: DRUG
Intervention: PLD
Description: PLD36mg/m2.d d1、d15，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip

Intervention type: DRUG
Intervention: DNR
Description: DNR 45mg/m2.d d1～3，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
Study: NCT00181753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope study
Description: 7 hours of primed constant infusion of stable isotope tracers.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope study
Description: 7 hours of primed constant infusion of stable isotope tracers.
Study: NCT05514652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low opioid anesthesia
Description: Multimodal low-dose opioid protocol for anesthesia based on ketamine, lidocaine and dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low opioid anesthesia
Description: Multimodal low-dose opioid protocol for anesthesia based on ketamine, lidocaine and dexmedetomidine
Study: NCT02614820

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Remote Ischemic Preconditioning Training Apparatus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning Training Apparatus
Study: NCT03057704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection flushed
Description: The investigator administers IV lidocaine and flushes it into the subject prior to administering propofol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine injection tourniquet
Description: Intravenous lidocaine: tourniquet
Study: NCT01876381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
Study: NCT01987557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rate group
Description: walking with a high cadence (steps per minute)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: magnitude treadmill group

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: regular treadmill walking
Study: NCT02373592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS and voice messaging
Description: This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermometry
Description: Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Thermometry
Description: Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
Study: NCT03400423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Oral administration of 1.2mg/kg of powdered caffeine with water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Oral administration of 1.2mg/kg of powdered caffeine with water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Oral administration of 1.2mg/kg of powdered caffeine with water.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise
Description: Moderate intensity exercise conducted on a treadmill. Moderate intensity exercise defined as (220-age)\*0.6.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise
Description: Moderate intensity exercise conducted on a treadmill. Moderate intensity exercise defined as (220-age)\*0.6.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise
Description: Moderate intensity exercise conducted on a treadmill. Moderate intensity exercise defined as (220-age)\*0.6.
Study: NCT04293198

Intervention type: DEVICE
Intervention: KODEX-EPD System
Description: The KODEX - EPD system is an open platform that uses any validated EP catheter to create real-time 3D images of the human heart. The KODEX occlusion viewer provides an indication of the occlusion status of the PV during cryoballoon PVI procedure

Intervention type: DEVICE
Intervention: Fluoroscopy with contrast dye
Description: Fluoroscopy with contrast dye is used to determine occlusion status during cryoballoon PVI procedures
Study: NCT04250701

Intervention type: OTHER
Intervention: Body Posture Assessment
Description: Application of three evaluations above at a one time.

Intervention type: OTHER
Intervention: Body Posture Assessment
Description: Application of three evaluations above at a one time.

Intervention type: OTHER
Intervention: Body Posture Assessment
Description: Application of three evaluations above at a one time.
Study: NCT02659085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine IV Infusion
Description: Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECT
Description: ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.
Study: NCT02051192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Led Exposure Therapy
Description: Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.